Yeah, I agree. For months we spoke about how the Q2/Q3 numbers would drive this stock. We were overbought/overpriced at $1 with nothing more than hype. So when the disastrous 10Q came out for Q1, we fell hard as expected. Now, we’re oversold and the chart points to a reversal. I think we’ll have a green week personally and if the Q2 10Q is good and we have some subsequent info that is positive, I can see us getting back to the .60-.70 range and rebuilding some hype. The only way we may get back over $1 is with some PR or outstanding Q3 sales, but I don’t think this thing is anywhere near dead. There’s also a good chance that we break into another business line. It’s obvious that ABMC got into covid test sales to infuse some cash into their struggling business. I’d have to think with their contracts in place, they’ll push to get into saliva testing as well. If so, that PR alone would spike this well past 52 week highs. We’ll see what happens.
News 
Market Data 
Discover 
AI
